Category Archives: Transhuman News

AP Bio Genetic Engineering Survey
AP Bio Genetic Engineering Survey.

By: Matthew C

Go here to see the original:
AP Bio Genetic Engineering Survey - Video

Inject a gene from a certain cold-water fish into a strawberry, and the strawberry can withstand colder temperatures. But would you still want to eat it?

Such advances in genetic engineering have implications for helping feed a growing, hungry world but a lot of people aren't too keen on eating those advances just yet.

Others wouldn't hesitate.

The difference reflects the "wild, messy debate" surrounding genetically modified food, with one of the more recent skirmishes centering on whether food labels should contain information about such ingredients, according to Nick George, president of the Midwest Food Processors Association, based in Madison.

Wisconsin's agriculture and food production industries find themselves smack in the middle of the debate.

"This is a big issue," George said. "It's not going away."

Neither, it seems, are genetically engineered crops in the American food chain.

The U.S. Department of Agriculture estimates that 93% of soybean acres and 85% of corn acres in 2013 were planted with genetically modified, herbicide-tolerant crop varieties.

The percentage of insect-resistant corn planted in 2013 stood at 76%, according to the USDA. The insect-resistant corn contains a gene from the soil bacterium Bt Bacillus thuringiensis. The bacteria produce a protein that is toxic to specific insects.

Consider that there are nearly 1.3 million dairy cows in Wisconsin, and some of them are no doubt eating corn with genetically modified ingredients.

See more here:
Debate rages over labeling genetically modified food

PUBLIC RELEASE DATE:

27-Jan-2014

Contact: Vicki Cohn vcohn@liebertpub.com 914-740-2100 Mary Ann Liebert, Inc./Genetic Engineering News

New Rochelle, NY, January 27, 2014Building on previous evidence showing that religious belief involves cognitive activity that can be mapped to specific brain regions, a new study has found that causal, directional connections between these brain networks can be linked to differences in religious thought. The article "Brain Networks Shaping Religious Belief" is published in Brain Connectivity, a bimonthly peer-reviewed journal from Mary Ann Liebert, Inc., publishers, and is available free on the Brain Connectivity website at http://www.liebertpub.com/brain.

Dimitrios Kapogiannis and colleagues from the National Institute on Aging (National Institutes of Health, Baltimore, MD) and Rehabilitation Institute of Chicago, IL, analyzed data collected from functional magnetic resonance imaging (fMRI) studies to evaluate the flow of brain activity when religious and non-religious individuals discussed their religious beliefs. The authors determined causal pathways linking brain networks related to "supernatural agents," fear regulation, imagery, and affect, all of which may be involved in cognitive processing of religious beliefs.

"When the brain contemplates a religious belief," says Dr. Kapogiannis, "it is activating three distinct networks that are trying to answer three distinct questions: 1) is there a supernatural agent involved (such as God) and, if so, what are his or her intentions; 2) is the supernatural agent to be feared; and 3) how does this belief relate to prior life experiences and to doctrines?"

"Are there brain networks uniquely devoted to religious belief? Prior research has indicated the answer is a resolute no," continues study co-author Jordan Grafman, Director, Brain Injury Research and Chief, Cognitive Neuroscience Laboratory, Rehabilitation Institute of Chicago. "But this study demonstrates that important brain networks devoted to various kinds of reasoning about others, emotional processing, knowledge representation, and memory are called into action when thinking about religious beliefs. The use of these basic networks for religious practice indicates how basic networks evolved to mediate much more complex beliefs like those contained in religious practice."

###

About the Journal

Brain Connectivity is the journal of record for researchers and clinicians interested in all aspects of brain connectivity. The Journal is under the leadership of Founding and Co-Editors-in-Chief Christopher Pawela, PhD, Assistant Professor, Medical College of Wisconsin, and Bharat Biswal, PhD, Chair of Biomedical Engineering, New Jersey Institute of Technology. It includes original peer-reviewed papers, review articles, point-counterpoint discussions on controversies in the field, and a product/technology review section. To ensure that scientific findings are rapidly disseminated, articles are published Instant Online within 72 hours of acceptance, with fully typeset, fast-track publication within 4 weeks. Tables of content and a sample issue may be viewed on the Brain Connectivity website at http://www.liebertpub.com/brain.

The rest is here:
Do brain connections help shape religious beliefs?

PUBLIC RELEASE DATE:

27-Jan-2014

Contact: Vicki Cohn vcohn@liebertpub.com 914-740-2100 x2156 Mary Ann Liebert, Inc./Genetic Engineering News

New Rochelle, NY, January 27, 2014Drugs comprised of single strands of DNA, called aptamers, can bind to targets inside tumor cells causing cell death. But these DNA drugs cannot readily get inside tumor cells on their own. Effective delivery of DNA aptamers using a natural polysaccharide as a carrier is described in an article in Nucleic Acid Therapeutics, a peer-reviewed journal from Mary Ann Liebert, Inc. publishers. The article is available on the Nucleic Acid Therapeutics website.

Tatyana Zamay and coauthors, Krasnoyarsk State Medical University, Siberian Branch Russian Academy of Sciences, and Center for Reproductive Medicine (Krasnoyarsk, Russia), and University of Ottawa, Canada, combined the polysaccharide arabinogalactan, obtained from the larch tree, with a DNA drug that binds to and disrupts the activity of vimentin, a structural protein required for cell division. Vimentin is often over-produced by tumor cells compared to normal cells.

In the article "DNA-Aptamer Targeting Vimentin for Tumor Therapy in Vivo" the authors show that an aptamer targeting vimentin inhibits tumor growth more effectively when it is administered as a mixture with arabinogalactan than alone.

"This work demonstrates the advancement of aptamer therapeutic application through increased bioavailability using a nontoxic polysaccharide based therapy," says Executive Editor Graham C. Parker, PhD.

###

Nucleic Acid Therapeutics is under the editorial leadership of Co-Editors-in-Chief Bruce A. Sullenger, PhD, Duke Translational Research Institute, Duke University Medical Center, Durham, NC, and C.A. Stein, MD, PhD, City of Hope National Medical Center, Duarte, CA; and Executive Editor Graham C. Parker, PhD.

About the Journal

See more here:
A natural sugar delivers DNA aptamer drug inside tumor cells

Startup Global Bioenergies uses genetic engineering to avoid one of the costliest steps in biofuel production.

Test plant: Global Bioenergies is adapting this test facility, owned by the European research organization Fraunhofer, to produce biofuels using a new process that avoids a costly distillation step.

Audi is investing in a startup, Paris-based Global Bioenergies, that says it can make cheap gasoline from sugar and other renewable sources. The strategic partnership includes stock options and an unspecified amount of funding.

As with conventional biofuel production, Global Bioenergies technology uses microrganisms to ferment sugars to produce fuel. But its process eliminates the second most costly part of producing biofuelsthe energy-intensive distillation step. And by making gasoline instead of making ethanol, the startup skirts a major problem hampering growth in biofuelsthe fact that the market for ethanol is saturated.

Global Bioenergies has demonstrated its technology in the lab and is building two pilot facilities to produce isobutene, a hydrocarbon that a partner will convert into gasoline through an existing chemical process. The larger of the two pilot facilities will be big enough to support the production of over 100,000 liters of gasoline a year.

The process addresses one of the key challenges with conventional biofuels productionthe fuel can kill the microrganisms that make it. In a conventional fermentation process, once the concentration of ethanol gets to about 12 percent, it starts to poison the yeast so that it cant make any more ethanol.

Global Bioenergies has genetically engineered E. coli bacteria to produce a gas (isobutene) that bubbles out of solution, so its concentration in the fermentation tank never reaches toxic levels. As a result the bacteria can go on producing fuel longer than in the conventional process, increasing the output of a plant and reducing capital costs.

The isobutene still needs to be separated from other gases such as carbon dioxide, but Global Energies says this is much cheaper than distillation.

The new process doesnt address the biggest cost of biofuels todaythe cost of the raw materials. Its designed to run on glucose, the type of sugar produced from corn or sugarcane. But the company is adapting it to work with sugars from non-food sources such as wood chips, which include glucose but also other sugars such as xylose.

Audis partnership with Global Bioenergies is part of push by the automaker to reduce greenhouse gas emissions in the face of tightening regulations. Audi recently announced two other investments in cleaner fuels. It funded a project to make methane using renewable energythe methane can be used to run Audis natural-gas fueled cars (see Audi to Make Fuel Using Solar Power). And it funded Joule Unlimited, which is using photosynthetic microrganisms to make ethanol and diesel (see Audi Backs a Biofuels Startup).

Read this article:
Audi Bets on Bio Gasoline Startup